trastu-leron...nice ring to it. the plus side
Post# of 148277
(Total Views: 467)
Posted On: 06/08/2022 10:36:09 AM
trastu-leron...nice ring to it.
the plus side is treatments are 99% of the time combo therapies. lerolimab will be combined with many other drugs in the future, monotherapy for anything is a longshot, except maybe HIV. even if the NASH data is outstanding, monotherapy is unlikely.
the down side is we get situations where remdesivir, the drug that the WHO says has zero benefit, is given royal status because of BP politics and must be combined with everything, even though we all know it is really only contributing 5% benefit, if any, to most all covid patients. leronlimab easily beats this metric in covid, with no side effects, yet here we are still on the sidelines because the endpoints in the trials were misguided and FDA has it out for us (and other small pharma).
for those new here, the covid CD 10 and CD12 trials DID show that people under 65 years old had vastly improved survival rates, but the FDA did not want to look at "subgroups" for what ever reason. called it cherry picking. they think that 75 year old cancer patients and 45 year old yoga instructors are equally healthy. the refusal to look at subgroups is the root cause for EUA denial. makes no sense. the other reason the trials failed is leronlimab was only allowed, by the FDA, to dose only TWICE in the first two weeks and while the data shows great improvement, the third and fourth weeks they declined. cytodyn wanted FOUR doses but was denied that luxury for some unknown mysterious reason.
yet the same FDA has given green lights to many vaccines and drugs with far less complete data.
things are changing, the mTNBC and NASH data is proving efficacy, and new people are taking notice.
but covid waves are here and growing, we need an EUA for covid now, 450 dying a day still. those 450 are currently ignored, especially on main stream media. cant remember the last time there was a daily death bulletin on the news. hard to believe. leronlimab can help many of these patients survive, today, with no side effects.
sorry to be repetitive to this board but we have many new eyes here and many more coming. it is up to us to educate them. leronlimab works and we know it. the data is proving it.
the plus side is treatments are 99% of the time combo therapies. lerolimab will be combined with many other drugs in the future, monotherapy for anything is a longshot, except maybe HIV. even if the NASH data is outstanding, monotherapy is unlikely.
the down side is we get situations where remdesivir, the drug that the WHO says has zero benefit, is given royal status because of BP politics and must be combined with everything, even though we all know it is really only contributing 5% benefit, if any, to most all covid patients. leronlimab easily beats this metric in covid, with no side effects, yet here we are still on the sidelines because the endpoints in the trials were misguided and FDA has it out for us (and other small pharma).
for those new here, the covid CD 10 and CD12 trials DID show that people under 65 years old had vastly improved survival rates, but the FDA did not want to look at "subgroups" for what ever reason. called it cherry picking. they think that 75 year old cancer patients and 45 year old yoga instructors are equally healthy. the refusal to look at subgroups is the root cause for EUA denial. makes no sense. the other reason the trials failed is leronlimab was only allowed, by the FDA, to dose only TWICE in the first two weeks and while the data shows great improvement, the third and fourth weeks they declined. cytodyn wanted FOUR doses but was denied that luxury for some unknown mysterious reason.
yet the same FDA has given green lights to many vaccines and drugs with far less complete data.
things are changing, the mTNBC and NASH data is proving efficacy, and new people are taking notice.
but covid waves are here and growing, we need an EUA for covid now, 450 dying a day still. those 450 are currently ignored, especially on main stream media. cant remember the last time there was a daily death bulletin on the news. hard to believe. leronlimab can help many of these patients survive, today, with no side effects.
sorry to be repetitive to this board but we have many new eyes here and many more coming. it is up to us to educate them. leronlimab works and we know it. the data is proving it.
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼